サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1349216

医薬品有効成分（API）の世界市場

Active Pharmaceutical Ingredients (API)

出版日
ページ情報
英文 727 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
医薬品有効成分（API）の世界市場
出版日: 2023年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 727 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

医薬品有効成分（API）の世界市場は2030年までに3,215億米ドルに達する

2022年に1,974億米ドルと推計された医薬品有効成分（API）の世界市場は、2022年から2030年にかけてCAGR 6.3%で成長し、2030年には3,215億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである革新的セグメントは、CAGR 6%を記録し、分析期間終了までに2,178億米ドルに達すると予測されます。ジェネリック医薬品セグメントは、今後8年間のCAGRが6.9%と予測されています。

米国市場は683億米ドル、中国はCAGR 6.6％で成長すると予測

米国の医薬品有効成分（API）市場は、2022年には683億米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間においてCAGR 6.6%で推移し、2030年までに519億米ドルの市場規模に達すると予測されます。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ5.6%と6%の成長が予測されています。欧州では、ドイツがCAGR 5.8%で成長すると予測されています。

調査対象企業の例

  • Alkem Laboratories Limited
  • Albemarle Corporation
  • Ajinomoto Co., Inc.
  • Apotex, Inc.
  • AbbVie, Inc.
  • Almac Group
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Alembic Pharmaceuticals Limited
  • Amsal Chem Pvt., Ltd.
  • Arch Pharmalabs Ltd.
  • AmbioPharm, Inc.
  • ACIC Pharmaceuticals, Inc.
  • American Pacific Corporation
  • ACS Dobfar S.p.A.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10061

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Active Pharmaceutical Ingredients (API) Market to Reach $321.5 Billion by 2030

The global market for Active Pharmaceutical Ingredients (API) estimated at US$197.4 Billion in the year 2022, is projected to reach a revised size of US$321.5 Billion by 2030, growing at a CAGR of 6.3% over the period 2022-2030. Innovative, one of the segments analyzed in the report, is projected to record 6% CAGR and reach US$217.8 Billion by the end of the analysis period. Growth in the Generic segment is estimated at 6.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $68.3 Billion, While China is Forecast to Grow at 6.6% CAGR

The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$68.3 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$51.9 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.6% and 6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Select Competitors (Total 266 Featured) -

  • Alkem Laboratories Limited
  • Albemarle Corporation
  • Ajinomoto Co., Inc.
  • Apotex, Inc.
  • AbbVie, Inc.
  • Almac Group
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Alembic Pharmaceuticals Limited
  • Amsal Chem Pvt., Ltd.
  • Arch Pharmalabs Ltd.
  • AmbioPharm, Inc.
  • ACIC Pharmaceuticals, Inc.
  • American Pacific Corporation
  • ACS Dobfar S.p.A.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Year 2021 in Review and Near-term Outlook
    • Prolonged Pandemic, Ukraine-Russia Conflict and Ensuing Economic Disruptions Impact Growth Outlook
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
    • COVID-19 Alters Pharmaceutical Industry and API Production Dynamics
    • COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages, Driving the Need to Revamp Domestic Industry Structure
    • Pandemic Leads US to Focus on Stockpiling & Localized Manufacturing to Rectify Supply Chain Flaws
    • Percentage Breakdown of API Manufacturing Facilities by Country for Drug Production in the US: 2021
    • Revamping Local Production Capacity
    • Knock-on Effect of COVID-19 on API Availability Incites Players to Reconfigure Supply Chain
    • COVID-19 Pandemic: A Wake-Up Call for API Seekers to Mitigate Supply Risks
    • Short-Term Strategies
    • Long-Term Strategies
    • Unprecedented Global Push to Expedite COVID-19 Vaccine Development to Spur Demand for APIs
    • Global Percentage of Individuals Vaccinated by Geographic Region for 2021 through 2025
    • Number of CMO Sites for Vaccine Production in Select Countries: 2020
    • Competition
    • Active Pharmaceutical Ingredients (API) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Active Pharmaceutical Ingredients (API) Competitor Market Share Scenario Worldwide (in %): 2022E
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Active Pharmaceutical Ingredients: A Prelude
    • Global Active Pharmaceutical Ingredients Market Set to Witness Rapid Growth
    • Regional Landscape
    • North America Dominates the Global API Market
    • US CDMOs to Gain from Mounting Concerns Over Excess Reliance On Chinese APIs
    • China Continues to Remain a Major Hub
    • COVID-19 Brings Europe's High Reliance on APIs Sourced from Outside under Spotlight
    • India Strives to Increase API Production to Attain Self Reliance in Pharmaceutical Production
    • Domestic Production and Import Share of Select API/Advanced Intermediates in India: 2019
    • Global PE Firms to Invest Heavily in Indian Intermediate Pharma Companies
    • Leading Players
    • Recent Market Activity
    • World Brands
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Sustained Increase in Drug R&D Spending to Drive API Market
    • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • Increased API Sourcing Creates the need for More Scrutiny of Suppliers for Best Quality Products
    • Preference for Specialized CDMO Contractors on the Rise
    • Strong Rise in Pharmaceutical Sales to Drive Demand
    • Global Prescription Drug Sales (In US$ Billion) for the Years 2000-2025
    • The AIC Approach for Faster Assessment of Viable Drug Candidates
    • Drug Makers Embrace Digital Technology Amidst COVID-19 Crisis
    • Digital Transformation Spending in US$ Billion in Pharma Sector: 2020 and 2027
    • Demand for HPAPIs on the Rise
    • AI Finds Growing Application in Drug Discovery and Development
    • Microdosing Beneficial for the Formulation of High Potency Ingredients
    • Growing Penetration of Generic Drugs Augments Market Prospects
    • Leading Drugs Facing Patent Expiry in the US in 2021
    • Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
    • Increasing Interest in Biopharmaceuticals Supports Market Demand
    • Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
    • Rising Number of Biologics Approvals Augurs Well
    • The U.S FDA Biologic NME Approvals for Years 2016 through 2021
    • Sponsor Market Cap for the FDA-Approved Biologic FDA NMEs (2020)
    • Growing Biosimilars Market Create Opportunities for APIs
    • Global Biosimilars Market in US$ Billion: 2020 & 2025
    • Growing Attention Towards Personalized Medicine Spurs Demand for Complex API
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • Increasing Sales of OTC Drugs Presents an Opportunity for APIs
    • Global OTC Drugs Market Breakdown by Product (in %): 2021E
    • Growing Prevalence of Infectious Diseases to Spur Growth
    • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Rising Incidence of Cancer & Need to Reduce Cancer-Related Mortality Spell Increased Demand
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Breakdown of Total Number of Cancer Cases by Type: 2020
    • Increasing Prevalence of Chronic Disorders Fuels Market Growth
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Rising Incidence of Cardiovascular Diseases Revs Up Opportunities
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Upsurge in ANDA Approvals Bodes Well
    • Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Novel Technology for Continuous Manufacturing of APIs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Active Pharmaceutical Ingredients (API) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for CNS & Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Orthopedic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Facts & Figures
    • Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • Market Analytics
    • TABLE 38: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • TABLE 65: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: China 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: China 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: China 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • Market Facts & Figures
    • Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • Market Analytics
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
    • TABLE 86: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: France 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: France 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: France 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • TABLE 113: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2014, 2023 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION